Short- and Long-Term Effects of Inpatient Cognitive-Behavioral Treatment of Adolescents With Anxious-Depressed School Absenteeism: A Within-Subject Comparison of Changes

2014 ◽  
Vol 36 (3) ◽  
pp. 171-190 ◽  
Author(s):  
Daniel Walter ◽  
Christopher Hautmann ◽  
Saada Rizk ◽  
Gerd Lehmkuhl ◽  
Manfred Doepfner
2003 ◽  
Vol 17 (2) ◽  
pp. 133-147 ◽  
Author(s):  
Sherry A. Falsetti ◽  
Brigette A. Erwin ◽  
Heidi S. Resnick ◽  
Joanne Davis ◽  
Amy M. Combs-Lane

Posttraumatic stress disorder (PTSD) is associated with significant impairment in functioning. Although improvement in PTSD symptoms following cognitive-behavioral treatment of PTSD has been demonstrated in numerous studies, improvement in functioning has yet to be fully explored. In addition to measures of PTSD, measures of functioning may help to identify more reliably broad-based change following cognitive-behavioral treatment of PTSD. A few studies have demonstrated short-term improvement in functioning following pharmacotherapy of PTSD. The current study is the first investigation to examine short- and long-term changes in adjustment and resources following cognitive-behavioral treatment of PTSD. Findings from this study suggest that, immediately following Multiple Channel Exposure Therapy (MCET), female trauma victims with PTSD and comorbid panic attacks reported improvement in work, marital, economic, and overall adjustment. In addition, 3 and 6 months following MCET, patients continued to experience improvement in work, marital, economic, parental, and overall adjustment. Future directions and clinical implications are discussed.


1998 ◽  
Vol 12 (1) ◽  
pp. 13-25 ◽  
Author(s):  
William Bradshaw

Cognitive-behavioral treatment (CBT) has rarely been applied as the primary treatment for the multiple, severe and persistent problems that characterize schizophrenia. This case study describes the process of CBT in the long-term outpatient care of a young woman with schizophrenia. The study highlights the adaptation of cognitive-behavioral strategies to the unique needs of schizophrenia and presents data regarding clinical outcomes in this case. Measures of psychosocial functioning, severity of symptoms, attainment of treatment goals and hospitalization data were used to assess change over the 3- year treatment period and at 1-year follow-up. Results indicate considerable improvement in all outcome variables and maintenance of treatment gains. These findings suggest the potential usefulness of cognitive-behavioral interventions in the treatment of schizophrenia.


SLEEP ◽  
2020 ◽  
Vol 43 (Supplement_1) ◽  
pp. A193-A194
Author(s):  
Y Li ◽  
A Vgontzas ◽  
J Fernandez-Mendoza ◽  
J Fang ◽  
K Puzino ◽  
...  

Abstract Introduction Both trazodone and cognitive-behavioral treatment of insomnia (CBT-I) are widely used to treat patients with chronic insomnia. Animal studies have shown that trazodone increases slow wave sleep (i.e., increased EEG delta power). However, no study to date has compared the long term effects of trazodone vs. CBT-I on spectral EEG activity during sleep in humans. Methods We addressed this question in a sample of 19 middle-aged men and women who received either trazodone (n=8) or CBT-I (n=11) treatment for 9 months. We examined delta (0.39-3.91 Hz), theta (4.30-7.81 Hz), alpha (8.20-11.72 Hz), sigma (12.11-14.84 Hz), beta (15.23-35.16 Hz) and gamma (35.55-49.61 Hz) relative power during NREM sleep after 3-month and 9-month of treatment. Results Compared to CBT-I, trazodone significantly increased relative delta power (p=0.05) and decreased relative sigma (p=0.004) and beta (p=0.05) power during NREM sleep across 9-month treatment. Furthermore, compared to CBT-I, trazodone significantly increased relative delta power (3-month: Δ2.00 ± 3.27 vs. Δ-2.63 ± 5.88, p=0.006, Cohen’s d=0.93; 9-month: Δ2.63 ± 4.11 vs. Δ-1.10 ± 3.93, p=0.006, Cohen’s d=0.93), while decreased relative sigma power (3-month: Δ-1.55 ± 1.75 vs. Δ0.90 ± 1.82, p=0.009, Cohen’s d=1.37; 9-month: Δ-1.33 ± 1.95 vs. Δ1.05 ± 1.79, p=0.014, Cohen’s d=1.28) during NREM sleep in 3-month and 9-month, respectively. Relative beta power (3-month: Δ-0.85 ± 0.60 vs. Δ0.35 ± 1.14, p=0.016, Cohen’s d=1.03;) was significantly decreased in 3-month treatment in trazodone group compared to CBT-I. Moreover, across 9-month treatment, relative sigma (p=0.040, ω p2 = 0.29) and beta (p=0.021, ω p2 = 0.12) power during NREM sleep were significantly decreased within trazodone group, while relative sigma power (p=0.096, ω p2 = 0.230) increased within CBT-I group. Conclusion Our findings suggest that trazodone, but not CBT-I, even after 9-month of use increases slow wave sleep and decreases high-frequency EEG power during NREM sleep. This effect may explain the long-term usefulness of trazodone in chronic insomnia patients with physiologic hyperarousal i.e., activation of the stress system. Further studies should examine this effect in large samples of insomnia. Support NIH C06 RR016499, UL1 TR 000127


Sign in / Sign up

Export Citation Format

Share Document